Last reviewed · How we verify

NCT05366686: NICE

The Effect of NICE Support Program on Frailty and Quality of Life in Patients With Heart Failure

Completed NA Last updated 10 July 2025
What this trial tests

NA trial testing NICE Support Program in Frailty in 240 participants. Completed in 8 February 2024.

Timeline
18 January 2022
Primary endpoint
8 February 2024
8 February 2024

Quick facts

Lead sponsorAi-Fu Chiou
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment240
Start date18 January 2022
Primary completion8 February 2024
Estimated completion8 February 2024
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Ai-Fu Chiou

Who can join

20 and older, any sex, with Frailty or Quality of Life. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This RCT study aims to examine effects of a NICE Support Program in heart failure patients. The following hypotheses were tested: patients who received the NICE program will report significant improvement in frailty , social support, anxiety, and depression, quality of life, and nutritional assessment at baseline,4 weeks, 12 weeks and 24 weeks.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effects of a multimodal support intervention (the NICE-Support programme) on frailty and quality of life in patients with heart failure: a randomized controlled trial.
    Wang TC, Hsieh YC, Yang CY, Lee CM, et al · · 2026 · cited 1× · PMID 41482005 · DOI 10.1093/eurjcn/zvaf187

Verify or expand the search:

Other recruiting trials for Frailty

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05366686.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing